These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21332732)

  • 21. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT.
    Nguyen S; Beziat V; Dhedin N; Kuentz M; Vernant JP; Debre P; Vieillard V
    Bone Marrow Transplant; 2009 May; 43(9):693-9. PubMed ID: 19011664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
    Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
    J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expansion of NKG2A-LIR1- natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/HLA-ligand mismatched patients following hematopoietic cell transplantation.
    Rathmann S; Glatzel S; Schönberg K; Uhrberg M; Follo M; Schulz-Huotari C; Kaymer M; Veelken H; Finke J; Fisch P
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):469-81. PubMed ID: 20044012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients.
    Pittari G; Fregni G; Roguet L; Garcia A; Vataire AL; Wittnebel S; Amsellem S; Chouaib S; Bourhis JH; Caignard A
    Bone Marrow Transplant; 2010 May; 45(5):862-71. PubMed ID: 19802033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference.
    Locatelli F; Pende D; Maccario R; Mingari MC; Moretta A; Moretta L
    Clin Immunol; 2009 Nov; 133(2):171-8. PubMed ID: 19481979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
    Loren AW; Porter DL
    Bone Marrow Transplant; 2008 Mar; 41(5):483-93. PubMed ID: 18026156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alloreactive natural killer cells promote haploidentical hematopoietic stem cell transplantation by expansion of recipient-derived CD4(+) CD25(+) regulatory T cells.
    Yu J; Ren X; Yan F; Li H; Cao S; Chen Y; Sun H; An X; Zhang N; Hao X
    Transpl Int; 2011 Feb; 24(2):201-12. PubMed ID: 21062369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers.
    Stern M; Passweg JR; Meyer-Monard S; Esser R; Tonn T; Soerensen J; Paulussen M; Gratwohl A; Klingebiel T; Bader P; Tichelli A; Schwabe D; Koehl U
    Bone Marrow Transplant; 2013 Mar; 48(3):433-8. PubMed ID: 22941380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of KIRs and KIR ligands in hematopoietic transplantation.
    Velardi A
    Curr Opin Immunol; 2008 Oct; 20(5):581-7. PubMed ID: 18675345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.
    Zhao XY; Chang YJ; Xu LP; Liu DH; Liu KY; Huang XJ
    Bone Marrow Transplant; 2009 Dec; 44(11):721-8. PubMed ID: 19377516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant.
    Velardi A; Ruggeri L; Mancusi A
    Curr Opin Hematol; 2012 Jul; 19(4):319-23. PubMed ID: 22555394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Donor lymphocyte infusions for acute myeloid leukaemia.
    Soiffer RJ
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):455-66. PubMed ID: 18790449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
    Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
    Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
    Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
    Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
    Ruggeri L; Capanni M; Urbani E; Perruccio K; Shlomchik WD; Tosti A; Posati S; Rogaia D; Frassoni F; Aversa F; Martelli MF; Velardi A
    Science; 2002 Mar; 295(5562):2097-100. PubMed ID: 11896281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural killer-cell KIR repertoire reconstitution after haploidentical SCT.
    Stern M; de Angelis C; Urbani E; Mancusi A; Aversa F; Velardi A; Ruggeri L
    Bone Marrow Transplant; 2010 Nov; 45(11):1607-10. PubMed ID: 20173785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia.
    Velardi A; Ruggeri L; Mancusi A; Aversa F; Christiansen FT
    Curr Opin Immunol; 2009 Oct; 21(5):525-30. PubMed ID: 19717293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Alloreactive NK cells enhance the effect of donor lymphocyte infusion in the management of relapsed lung cancer after haploidentical hematopoietic stem cell transplantation].
    Yu JP; Sun HY; Li H; Cao S; Xin N; Ren XB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):164-9. PubMed ID: 19236771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.